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ABSTRACT
The Kinetics of Influenza A (A/California/4/2009-H1N1) and B (B/Phuket/3073/2013
(BYam), B/Brisbane/60/2008 (BVic)) Virus Infection in Ferrets
Demi L. Erickson
Thesis Director: Victor C. Huber, Ph.D.
Influenza is a persistent threat to individual and global health. Seasonal influenza
kills nearly 500,000 people globally each year. Influenza viruses have circulated within
the human population, causing a significant disease burden. In order to create the most
effective antiviral therapies, knowledge concerning all lineages of influenza must be
studied accurately and thoroughly. The influenza virus itself is not always responsible for
these mortalities, rather, the secondary bacterial infections associated with death. In order
to protect the population and examine the secondary infections that arise, the kinetics of
influenza must be studied entirely. To understand the kinetics, researchers are turning to
the use of laboratory experimentation using ferrets as an effective model. This is done
through the use of common laboratory procedures such as TCID50’s and
hemagglutination assays. Through the use of these procedures, the kinetics of influenza A
and B can be confirmed. Within this study, it was confirmed that influenza A infects both
the upper and lower respiratory system, while influenza B infects the upper respiratory
tract but fails to reach the lower lungs. Understanding the kinetics of influenza is the first
step toward creating effective therapies to reduce the mortality and illness associated with
the influenza virus infection.
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CHAPTER ONE
Introduction

Importance of Understanding Influenza
Influenza is a highly contracted and contagious viral disease, infecting 5-20% of
the world population each year (WebMD, 2020). According to the World Health
Organization, tens of millions of people are infected with influenza during the flu season.
Serious complications are rare for people infected with influenza, however, in the United
States, there are more than ten thousand deaths due to influenza infection each year
(Center for Disease Control and Prevention, 2020). According to the Center for Disease
Control and Prevention (CDC), during the 2019-2020 flu season, starting October 1,
2019, there were an estimated 32 million cases of influenza-like illnesses globallly. In the
most recent flu season (2019-2020), there were 310,000 hospitalizations and 18,000
deaths linked to influenza, and the season has not concluded as of the writing date
(Center for Disease Control and Prevention, 2020).
In most cases, influenza infections are not fatal. However, in some cases,
treatment is needed to prevent further complications. If influenza is allowed to progress,
moderate and severe secondary infections may arise. These progressive infections can
develop into bronchitis, pneumonia, or sinus infections (Miko et al., 2019). Sinus and ear
infections are examples of moderate complications that can arise from influenza. Serious
complications that are triggered by an influenza infection include myocarditis,
encephalitis, myositis, and multi-organ failure (Center for Disease Control and
Prevention, 2019). Not only can influenza infection trigger secondary infections, it may
8

make chronic medical conditions worse (Center for Disease Control and Prevention,
2019). Since influenza is a respiratory infection, patients with underlying respiratory
complications possess a substantial risk when contracting influenza.
There are many preventative procedures that should be considered for influenza,
such as increased personal hygiene and receiving an annual flu vaccination. Flu vaccines
have become increasingly popular and are easily accessible to the general public. The
CDC estimates the flu vaccine as 40 to 60 percent effective among the overall population
during seasons when circulating influenza viruses are well-matched with the strains
included in the vaccine (Center for Disease Control and Prevention, 2020). In the most
recent flu season (2019-2020), the CDC estimates that the vaccine has only been about 45
percent effective. With the prevalence and known history of influenza, one might think
that a more accurate and effective vaccination could be accessible, however, since it is
difficult to predict which of the multiple strains or subtypes of influenza will be
circulating in a given year, constant research is needed to prepare for the upcoming flu
season.

History of Influenza A and B in Humans
Influenza first became recognized in 1889 as a bacterial infection, starting as an
epidemic in Bukhara, Uzbekistan, that developed into a pandemic of Russian influenza
within the same year (Erkoreka, 2009). An epidemic is defined as a disease that affects a
large number of people within a community, while a pandemic is defined as an epidemic
that has spread over multiple countries or continents (Intermountain Healthcare, 2020).
The classification of influenza from an epidemic to a pandemic within the same year
demonstrates the high transmissibility of the virus. During this time, railways and steam
9

trains were increasing in numbers, spreading the disease at alarming rates. A few years
after the influenza pandemic had circulated the world, most clinicians accepted that
“Pfeiffer’s bacillus”, a bacterium, was the leading cause of influenza. In 1918, influenza
continued to spread around the world, infecting billions of people. During this wave, an
estimate of 50 million to 100 million people died as a result of influenza infection
(Hageman, 2020). Society was unable to keep this infectious disease under control with
the therapies they were using to approach this pandemic. However, in 1933, the National
Institute for Medical Research was able to identify influenza as a new class of pathogenic
viruses (Brennan, 1987). This new classification of pathogens allows a way to distinguish
different viral strains utilizing the haemagglutinin (H) and neuraminidase (N) antigens on
the virus coat. In subsequent years, different strains such as the Asian flu (1957, H2N2),
Hong Kong flu (1966, H3N2), and the 1976 swine flu (H1N1) demonstrated how new
strains of influenza could emerge from livestock and wild animals.
Of the four recognized influenza types, A, B, C, and D, influenza A causes the
most morbidity in humans (Seladi-Schulman, 2019). Influenza A viruses (IAVs) are the
only known influenza viruses to cause flu pandemics around the world (Center for
Disease Control and Prevention, 2019). This strain of influenza can be found in many
different species including but not limited to humans, birds, and swine (Center for
Disease Control and Prevention, 2018). Due to the large diversity of hosts and influenza’s
ability to change genetically, influenza A viruses are very diverse. Although influenza A
is commonly thought to be one strain, many different subtypes arise to cause global
epidemics. These viruses are divided into many subtypes based on the surface proteins H
and N. There are 18 different H subtypes and 11 different N subtypes (Seladi-Schulman,
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2010). There are currently 131 subtypes detected in nature, with A (H1N1 and H3N2)
circulating in humans most predominantly (Center for Disease Control and Prevention,
2019). The current H1N1 virus strain emerged in the spring of 2009 and has continued to
undergo small genetic changes that yield changes to its antigenic properties, making this
virus hard to target and allowing for elevated infectivity (Cheng & To, 2012). It is
estimated that influenza A accounts for 75 percent of confirmed seasonal infections.
(Seladi-Schulman, 2019).
While influenza B viruses (IBVs) are unlike influenza A viruses in terms of
genetics; symptoms associated with these two viruses are generally similar (Anthony,
2018). IBVs are classified into two lineages: B/Yamagata and B/Victoria (Yang et al.,
2012). Given the fact that Influenza B viruses mutate at a much slower rate than IAVs in
terms of genetics and antigenic properties, and that the primary host for IBV is human,
there is a reduced chance of a possible pandemic concerning influenza B. Influenza B is
commonly spread from human to human and is highly contagious similar to influenza A
(Center for Disease Control and Prevention, 2019). While influenza A accounts for nearly
75 percent of confirmed flu cases, influenza B accounts for the remaining 25 percent
(Seladi-Schulman, 2019). Influenza B is still a strain that raises concern, however, as
influenza B viruses have been perceived to circulate in particular time periods and
geographical areas. The two strains of influenza B, Vic87 and Yam88, have been known
to decline in infection magnitude and then re-emerge later in time, causing epidemics of
influenza B viruses to fluctuate both periodically and geographically (Yang et al., 2012).
Influenza B may not appear to be as high of a threat as IAV due to the slower evolution
and antigenic drift, however, various mechanisms of insertion, deletion, and reassortment
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within different lineages increase the genetic diversity of influenza B (Dudas et al.,
2014). Nonetheless, both influenzas raise concern to the public and the research behind
the two types of influenza is constant and continuous.

Ferrets as a Model System for Influenza Study
For many years prior, mice have been used as a model system to study influenza
viruses (Belser et al., 2011). The individual animals were low cost, readily available, and
had extensive availability for the use of reagents and for transgenic lines with targeted
gene disruptions. It was later found that most human influenza strains do not replicate
efficiently in mice without prior virus adaptation, and the clinical signs commonly found
in humans were not present in mice (Belser et al., 2011). Mice were deemed a poor
model for the study of influenza, thus leading to the guinea pig model. Guinea pigs
support the replication of influenza without prior adaptation, but like mice, do not
replicate the clinical signs experienced by humans (Belser et al., 2011). Non-human
primates were then used as a model, but proved to be exceedingly large and costly, and
ethical considerations limited the use these species as a model (Belser et al., 2011). An
improved model was needed, and the ferret was then introduced to the laboratory setting.
The use of ferrets for the understanding of influenza viruses has broken ground in
scientific research. Ferret models (Mustela putorius furo) have been established for many
viruses that lead to respiratory infections (Matsuoka et al., 2009). Ferrets are a common
mammalian model for certain studies as they are relatively small in size and they possess
the ability to emulate numerous clinical features associated with human disease
(Matsuoka et al., 2009). This is especially the case in regard to influenza. They provide
an ideal model for an influenza study as they are naturally susceptible to human-adapted
12

influenza viruses, and when infected they display similar symptoms as humans
(Matsuoka et al., 2009). These symptoms include fever, lethargy, nasal discharge,
sneezing, and coughing. Not only do the two species exhibit similar clinical signs, the
lung physiology of humans and ferrets is also relatively similar (Belser et al., 2019). The
human and avian influenza viruses show similar patterns of binding to sialic acids on the
cell surface, which are distributed throughout the respiratory tract in both humans and
ferrets (Besler et al., 2019). Ferrets display a high susceptibility to influenza virus, and in
1933, it was shown that an infected ferret is able to transmit the virus to healthy
individuals within the ferret species (Smith et al., 1933). Human and avian viruses
replicate efficiently in the respiratory tract of ferrets without prior adaptation, and
enhanced pulmonary spread of virus is seen following infection with some highly
pathogenic avian influenza (HPAI) viruses (Belser et al., 2011). Numerous symptoms
found in humans during a seasonal influenza outbreak were also present in ferrets
following experimental inoculation with these strains via the intranasal route (Moore et
al., 2014). Elevated body temperatures can be detected as early as one day postinoculation and nasal discharge along with sneezing can be observed up to seven days
post-inoculation (Zitzow et al. 2002). Upon collection of data, the blood and/or tissue
samples can be collected from an inoculated ferret, and the presence of virus can be
quantified. The use of ferrets in the study of influenza has proven to be highly successful
and has offered crucial information for the understanding of influenza.
Using ferrets as models to study the infectivity of influenza A and B in the upper
and lower respiratory tract have proven useful to the understanding of these viruses.
Studies were previously conducted using autopsy material from humans, so only changes
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associated with lethal outcomes and late-stage disease had been characterized
(Taubenberger & Morens, 2008). The infection of influenza goes far beyond this, varying
with clinical progression and length of the disease before death. Concern about the
emergence of an influenza pandemic caused by an HPAI virus (influenza A strain) makes
reviewing the pathology of previous pandemics relevant. Both types of influenza display
a standard pattern of infection in humans with an exponential increase in virus titer,
which peaks around two to three days post infection, followed by an exponential decrease
until days six to eight, with the virus titer ultimately undetectable in both the upper and
lower respiratory systems (Baccam et al., 2006). Aside from this, influenza A and B are
known to differ in the rate of infectivity and the direction in which the virus travels,
loosely defined as kinetics. The difference in kinetics between the two types is defined
around the region of infection in the respiratory tract, specifically the upper and lower
portions.
Unlike influenza B, influenza A replicates in both the upper and lower respiratory
tract (Baccam et al., 2006). IAV can be detected in both the nasal passage and in the
lower respiratory tract (lungs), for the duration of nine days post-inoculation (Kim et al.,
2015). The kinetics of influenza A are commonly studied, but information concerning the
kinetics of influenza B is not nearly as abundant. Few studies with reliable data have been
conducted concerning the lower and upper respiratory infections of influenza B. In a
study by Kim (2015), the presence of virus was found in the nasal turbinate, but all
samples collected showed no presence of influenza B in the trachea or lung. This is
intriguing as influenza virus is thought to replicate in the epithelial cells throughout the
respiratory tree (Taubenberger & Morens, 2008). People with chronic lung disease are
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cautioned by the CDC to be cautious during the flu season as they are more at risk for the
likelihood of severe disease and death. If influenza B is deemed to be absent in the lungs,
those with chronic lung disease that have contracted an IBV can rest assured knowing
that the likelihood of mortality is lowered. The absence of knowledge concerning the
kinetics of influenza B suggests that more research is needed if the number of people
infected by influenza is to decrease.

Influenza and the General Public
With the current coronavirus disease of 2019 (COVID-19) pandemic, it is evident
why viral kinetics and the possible outcomes of viral infections should be studied. Every
year, seasonal influenza makes a return with the possibility of catastrophic consequences
when pandemics occur. While the importance of influenza pandemics has been wellnoted since 1918, the virus continues to infect thousands and kill an average of 500,000
people globally each year (Fauci & Collins, 2012). The cases of influenza during a
“normal” influenza season in the United States can reach extreme numbers of 20 to 50
million cases of influenza and influenza-like illnesses (Clayville, 2011). The virus is
continuously undergoing extensive genetic changes in addition to possessing the ability
to transfer between species (Webster & Govorkova, 2015). This concept leads to high
vulnerability in humans. If an event similar to the previously described occurs, a global
health disaster can arise, such as the 1918 influenza pandemic. The 1918 pandemic killed
an overwhelming fifty to one hundred million people worldwide (Institute of Medicine,
2005). Not only did an extreme mortality rate affect the public, the world encountered
enormous social and economic disruption. Influenza circulates widely and is constantly
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evolving toward pandemic capability, as was seen in the pandemic of 1957, 1968, and
2009. This indicates a clear danger of future pandemics caused by the influenza virus.
One of the goals present in pandemic influenza research is to recognize and
predict how viruses are evolving in wild animals toward a phenotype that is threatening
to humans (Fauci & Collins, 2012). This research could allow society to stay one step
ahead of the virus and be able to prepare for any future outbreaks. However, due to the
constant evolution of the virus, continuous research is needed to keep up with the genetic
changes undergone by influenza. If staying one step ahead fails and an outbreak occurs,
information on how to decrease mortality of the virus in those already infected is crucial
as well. Influenza in its entirety must be studied to prepare for a large outbreak, this
includes thorough study of the kinetics of influenza infection. Currently, little is known
about the kinetics of influenza during infection due to its constant genetic evolution.
Numerous studies are in place to try to comprehend the entirety of influenza and by the
analysis and discovery of new information, influenza infection can be hindered or
altogether stopped through the development of new antiviral therapies.

Purpose
Many studies have been conducted on the infectivity and kinetics of influenza A,
however, influenza B has not been studied as thoroughly. It has been determined that
influenza A has the ability to first infect the upper respiratory tract while later traveling to
the lower respiratory system. Influenza B has been determined to infect the upper
respiratory system, however less is known about its activity in the lungs. The kinetics of
influenza A were tested and verified through this research and the kinetics of influenza B
were investigated. The kinetics of influenza B were discovered and analyzed through the
16

use of ferrets and numerous laboratory procedures. Identifying and understanding the
kinetics of influenza B infections will provide crucial information toward the
understanding of the virus and could ultimately lead to development of more effective
antiviral therapies and vaccines.
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CHAPTER TWO
Materials and Methods

Timeline of Events
Male ferrets from an influenza free ferret colony at Marshall Farms were brought
to the University of South Dakota (USD), Sanford School of Medicine’s animal facility.
Ferrets were acclimated for fourteen days, then tested to confirm that the antibody levels
were in compliance with titer levels against the three viruses used in this study. All of the
procedures and experiments were conducted within biosafety level 2 facilities and in
accordance with parameters set individually by the Institutional Animal Care and Use
Committee and the Institutional Biosafety Committee of USD. The experiment took place
over a course of nineteen days post-inoculation. Days -4 to Day 0 were spent preparing,
replicating, and plating cells for the remainder of the study. On day 0, different groups of
ferrets (n=4) were inoculated with B/Phuket/3073/2013 (BYam), A/California/4/2009H1N, and B/Brisbane/60/2008 (BVic). On days one through ten, nasal washes were
collected from the four ferrets and Madin-Darby Canine Kidney (MDCK) cells were
inoculated with nasal washes to determine whether virus was present in the nasal area. To
determine presence of virus, the MDCK cells were incubated for a period of 72 hours
before the virus titer was read and quantified. To confirm the presence of virus,
individual wells of the diluted nasal wash samples (n=4 per dilution) were tested for their
ability to bind red blood cells, indicating presence of virus in the well. Upon completion
of all data collection, the results were then analyzed and compared.
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MDCK Growth Medium
MDCK growth medium was essential to support cellular growth in an artificial
environment, providing nutrients necessary for cultured cells to survive and proliferate.
Growth medium also provides the correct osmolality and pH for cells to thrive and
replicate. Serum-containing, minimum essential medium (MEM) was used for this study.
MEM includes higher concentrations of amino acids allowing for a closer approximation
to the protein composition of mammalian cells. Growth medium was used for the growth
of healthy cells as well as an additive to ensure MDCK cells reached a confluency of
3x105 MDCK cells per 500 l of media. This allowed the cells used for infection with
nasal wash to remain at similar quantities for each sample dilution analyzed. All cell
culture techniques were performed under a sterile hood using aseptic techniques to ensure
the solution was free of all microorganisms by sterilization. A 500 mL sterile filter-top
(Corning 430626) was attached to a one-liter sterile bottle, later connecting the two
components to a pump system. To the filter-top, 100 mL 10X MEM (GIBCO 11430), 50
mL of Fetal Bovine Serum (FBS)- Hyclone (previously heated-inactivated at 56C for 30
minutes), 10 mL of Antibiotic/antimycotic solution and 10 mL MEM Vitamin solution
was added to the filter-top. Fetal Bovine Serum was included because of its high quantity
of hormones, carrier proteins, and macromolecular proteins allowing for growth
enhancement of the MDCK cells. Antibiotic/antimycotic was added as a prophylactic to
prevent contamination, and vitamins were added to the growth medium due to the
inability of MDCK cells to synthesize vitamins independently. Ten mL L-glutamine was
added to serve as an auxiliary energy source, providing nitrogen for the synthesis of
proteins as the cells are rapidly dividing. One mL Gentamicin (10 mg/cc) was added for
19

its anti-bacterial efficacy. The total volume of the sterile filter-top was brought to 500 mL
with ddH2O (approximately 331 mL). Once filtration was complete, the pump was
stopped and the resulting pressure was released. To the empty filter-top, 30 mL Sodium
Bicarbonate (NaHCO3) was added to maintain the pH in the presence of 4-10% carbon
dioxide. The volume was brought up to 500 mL using approximately 470 mL ddH2O
(double-distilled). Upon completion of this procedure, the color of the MDCK Growth
Medium was analyzed for a correct pH balance of 7.4. The contents of the bottle were
then stored at 4C.

MDCK Infection Medium
Along with MDCK growth medium, MDCK infection medium is also essential.
The infection medium acts as a viral infection enhancer that allows the facilitation of
viral penetration, ultimately enhancing productive viral infection of MDCK cells. This
procedure was performed under a sterile hood using aseptic techniques. The filtration
system was assembled, in the same way as for the Growth Medium. To the sterile filtertop, 100 mL 10X MEM, 40 mL 7.5% Bovine Serum Albumin (BSA)-Sigma (15 g BSA
in 200 mL ddH2O), 10 mL Antibiotic/antimycotic solution, ten mL MEM Vitamin
Solution, ten mL L-glutamine, and 1 mL Gentamicin (10mg/cc) was added. The volume
was brought to 500 mL with 329 mL ddH2O. Thirty mL Sodium Bicarbonate was added
to the filter-top along with 470 mL ddH2O, the pump system was started and upon
completion of filtration, the medium was mixed and analyzed for correct color, indicating
pH. The contents were stored at 4C.
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Cell Culture
Cells were plated using 48-well sterilized plates. The flask containing MDCK
cells and growth medium was viewed under a microscope to ensure a monolayer was
produced during cell growth and replication. The growth medium was removed from the
cell flask and the cells were washed once with sterile PBS. Washing with PBS allows for
removal of dead cells and excess serum in the growth medium that inhibits trypsin. The
cells were harvested using 9 mL sterile PBS and 1 mL 0.5% trypsin, adding this solution
to the flask, and allowing incubation for 1 hour. Trypsin allows for the removal of
calcium from the cell solution, breaking and separating the cadherins in which the cells
are held together as well as cutting focal adhesions that anchor the cell to the culture flask
(Brown et al., 2012). After incubation, the cells were visualized to ensure the cells were
suspended in solution. An aliquot of trypsinized cells was collected and centrifuged for
three minutes at 2500 rpm. The supernatant was removed completely so no residual
PBS+trypsin covered the cell pellet. The pellet was resuspended in 10 mL of MDCK
growth medium. In a small test tube, 400 µL of MDCK growth medium was added with
100 µL of the resuspended cell solution. To ensure confluency of live cells and to reach
the desired cell count, 500 µL of Trypan Blue was added to the solution. Trypan blue is a
dye used to quantify live cells by labeling dead cells exclusively. Because live cells have
an intact cell membrane, trypan blue cannot penetrate the cell membrane of live cells and
enter the cytoplasm. In a dead cell, trypan blue passes through the porous cell membrane
and enters the cytoplasm. Ten µL of this solution was added to a hemocytometer and was
visualized under a microscope. The intact cells were counted and MDCK growth medium
was added to achieve the desired density of cells per well, 3 x 105. The MDCK cells were
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then plated on a 48 well plate, with 500 µL in each well. Due to the high growth rate of
the cells, the cells were split every three days to allow for appropriate space for growth.

TCID50
One method used to verify the viral titer was the fifty-percent tissue culture
infective dose (TCID50). This procedure signifies the concentration at which 50% of the
cells are infected. To begin the TCID50, the collected nasal wash was diluted using 10fold serial dilutions. To obtain the desired dilutions, 900 µL of MDCK infection medium
was added to a series of ten disposable glass test tubes. After adding medium, 100 µL of
the desired virus sample (nasal wash or lung) was added to the first test tube, to obtain a
total volume of 1 mL. The samples and all test tube dilutions were kept in an ice bath
during the procedure to ensure the infectivity was kept intact. The samples were vortexed
before addition to the plate to ensure proper creation of a homogeneous mixture. From
the MDCK cells plated a day prior, the medium of the MDCK monolayers was removed
with a glass pipet. The cells were washed with two separate additions of sterile 1X PBS
(pH=7.43). After the second wash and removal of PBS, 50 µL of the dilutions were
added to their respective wells containing the confluent MDCK monolayers. Nasal wash
dilutions were added starting with medium as a control and then proceeding to add the
lowest dilution first. Adding the lowest dilution first ensured a higher concentration of
infected nasal wash was not carried to those with lower concentrations. Medium was
used as a control in wells A1-A4, as displayed below in Figure 2.1.
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Figure 2.1: 48-well plate configuration for serial dilutions of virus stock used for TCID 50 protocol. Red
values indicate dilution of nasal wash.

The cell plates were then incubated at either 37C (for IAV) or 33C (IBV) for
one hour, allowing for optimal infectivity, with gentle tapping every 15 minutes to ensure
the sample was evenly distributed across the monolayer of cells. Using 40 mL of MDCK
infection medium, 40 µL of TPCK-trypsin was added to the test tube. The working
solution was made for a ratio of 1 µL of 1 mg/mL stock solution per milliliter of MDCK
infection medium. The cell plates were removed from the incubator and the virus
inoculum was aspirated off the MDCK monolayer, from most dilute to least, to prevent
the dragging of higher concentrated virus across the samples. After aspiration, 500 µL of
contents containing MDCK infection medium supplemented with TPCK-trypsin, was
added to each individual well. The plates were incubated at 37C (IAV) or 33C (IBV)
for 72 hours and were observed daily for cytopathic effect (CPE).

Preparation of CRBCs
Influenza viruses have an envelope protein, known as hemagglutinin, that binds to
sialic acid receptors on cells. The virus will also bind to red blood cells causing the
formation of a lattice. The binding to red blood cells is the basis of the rapid assay that
23

determines the quantity of virus present. To prepare the red blood cells needed for the HA
Titer, chicken red blood cells which are shipped in Alsevers solution to prevent
coagulation of the blood cells, were resuspended and transferred in 12 mL increments
into two 15 mL conical tubes. The cells were centrifuged using an Eppendorf Centrifuge
5910 R, for four minutes at 1,338 rpm (357xg) and were kept at 25C. After
centrifugation, the supernatant was removed, taking special care to preserve the RBC
layer, but removing the white blood cell (WBC) layer. Ten mL of (1X) PBS was added to
each tube with the cell layer. The mixture was then centrifuged again for four minutes at
1,338 rpm (357xg) at 25C. The supernatant was then disposed carefully to preserve the
cell layer, but removing all PBS added previously. Ten milliliters of (1X) PBS was added
to each of the tubes. The mixture was centrifuged for 20 minutes at 800 rpm and kept at a
temperature of 25C. The supernatant was removed once again, to ensure no PBS
remained in the conical tube. In a sterile bottle, 100 mL of sterile (1X) PBS was added
and 0.5 mL of RBC from the conical tube was added to the PBS. The RBCs were
carefully resuspended using a pipette, until the mixture was homogenous. Upon
completion, the 0.5% CRBCs were stored at 4C.

HA Titer
This test relies on the hemagglutination activity of influenza hemagglutinin and
the ability of HA-specific to agglutinate erythrocytes. Influenza virus particles contain a
homotrimeric glycoprotein on their surface, hemagglutinin (HA), which causes
erythrocytes to agglutinate. Hemagglutinin binds to sialic acid receptors on the cells and
will also bind to erythrocytes causing the formation of a lattice. This property allows for
the quantification of virus present in a sample.
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After the 72 hour incubation, the MDCK plates previously inoculated with nasal wash
were transferred to a 96 well plate. A round-bottom 96-well plate was used to allow the
red blood cells to settle in the bottom of the well and to decrease the surface area and
volume of individual wells. From the TCID50 plates, 50 µL from each incubated well was
transferred to a new well in the 96-well round-bottomed plate. Following the transfer, 50
µL of 0.5% CRBC solution was added to each well to bring the volume to a total of 100
µL. The plates were allowed to incubate at room temperature for 30 minutes. The plates
were then observed and analyzed, with settling of the erythrocytes into a pellet indicating
the absence of a virus (negative). If settling was not observed and agglutination occurred,
this indicated that the virus was able to bind to the CRBC solution, indicating that virus
was present in the specific sample at the indicated dilution.
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CHAPTER THREE
Results and Data

Clinical Data
Weight, temperature, and infection of the upper and lower respiratory system
were monitored daily in the experimentally infected ferrets. According to a study
conducted by Lee (2010), the most frequent clinical symptoms of influenza infection
included fever, nausea, and diarrhea. Nausea and diarrhea would lead to a decrease in
weight, an easy variable to measure in a laboratory setting. Increased body temperature,
pyrexia, was proven to be the most frequent clinical symptom noted by those infected
with influenza (Plaza, 2016). Finally, TCID50 and HA titers are ways to both confirm and
quantify the presence of influenza within the respiratory system. Together, these
variables were able to characterize the ferret response and virus shedding and localization
after infection by two types of influenza. The strain of influenza A used within this study
includes A/California/4/2009-H1N1 (Cal09). The two strains of influenza utilized in this
study consist of B/Phuket/3073/2013 (BYam lineage, B/Phuket) and B/Brisbane/60/2009
(BVic lineage, B/Brisbane).

A/California/4/2009-H1N1
The weights were recorded for ferrets infected with the Cal09 virus. This influenza
A virus is similar to what was used in previously published studies and provides a basis for
the research conducted on influenza B. The animals were monitored for weight loss daily,
in grams, over a period of nine days. The baseline used for the comparison of data is defined
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as the data collected on the day of inoculation, representing the norm. All of the ferrets
inoculated with the IAV showed a decrease in weight, with peak percent weight losses
being 9.19% and 8.52%. This data is presented in Figure 3.1 below. A value of (1) on the
x-axis indicates day zero, in which the ferrets were inoculated. All ferrets included in the
experiment concerning infection with influenza A exhibited a decrease in weight starting
the day after inoculation and remained below the baseline for the duration of the study.
Although the weights remained below the initial weight prior to inoculation for the entirety
of the experiment, 43.75% of all weights noted, exhibited weight gain when compared to
the weight recorded on the previous day. When compared to the baseline weight recorded,
the ferrets exhibited weight changes of -2.72%, -5.50%, -3.91%, and -3.67% on the day
concluding this experiment. Rectal temperatures were also recorded over the course of the
experiment. A normal temperature for a ferret ranges between 37.8 to 39 degrees Celsius
(Leesville Animal Hospital, 2016). The data collected for temperature comparison
throughout the experiment can be seen below in Figure 3.2. The animals exhibited body
temperature changes ranging from 1.39 degrees Celsius to -0.95 degrees Celsius from the
initial temperature recorded on day 0. Of the sixteen temperatures recorded postinoculation, 62.5% of all temperatures recorded, showed an increase from the baseline
through the duration of the study. Although two ferrets exhibited decreases in body
temperature for day one post-inoculation, the temperatures eventually rose to above normal
body temperature recorded prior to infection. All ferrets inoculated with Cal09 showed an
elevated body temperature at the end of the experiment, day four (depicted by five on the
x-axis in Figure 3.2).
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Figure 3.1 (left): Percent of weight change in ferrets infected with Cal-09 virus.
Figure 3.2 (right): Percent of temperature change in ferrets infected with Cal-09 virus.

In addition to weight and temperature change, a virus titer was conducted for the
nasal wash and the lungs. The data showed an initially large presence of influenza virus
in the nasal wash. The TCID50 values for the ferrets infected with Cal09 can be compared
and viewed below in Figure 3.3. The nasal wash data from the four ferrets were
compared based on the TCID50 value of the virus. On day one, the four ferrets showed an
average TCID50 value of 104.5 TCID50/mL. This value denotes the peak concentration of
Cal09 taking place 24 hours after inoculation. The average TCID50 value then proceeded
to steadily decrease over the course of four days to a TCID50 value of near 101
TCID50/mL, indicating little to no viral activity in the nasal wash near the end of the
experiment.
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Figure 3.3: TCID50 values for ferrets UL-71, LL-72, UR-73, LR-74, over the course of four days.

Along with the nasal wash titer, data were collected to observe the presence of
Cal09 in the lungs of the four ferrets. Lung titers were conducted upon euthanasia of the
animals, taking place after nasal wash data was completed. Different sections of the lung
were collected and combined into a single homogenate. The data in Figure 4.3 shown
below, illustrates the TCID50 combined lung titer for ferrets inoculated with Cal09. Aside
from the values obtained, these data show that the virus was able to reach not only the
nasal wash, but also the lungs. Virus in the nasal turbinates decreased over the course of
four days post-inoculation, however, virus titers performed on the lung samples after
nasal wash data collection showed substantial viral activity, indicating the movement of
influenza A from the upper to the lower respiratory tract. Upon lung data collection on
day four, the data showed an average TCID50 value of 3.7x104 TCID50/mL for the four
ferrets, indicating viral activity in the lower respiratory system while virus was no longer
detected in the nasal wash.
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Figure 3.4: Combined lung titers for ferrets inoculated with Cal-09 virus.

B/Brisbane/60/2008 (BVic)
The ferrets infected with B/Brisbane/60/2008 (BVic) were weighed on the day of
inoculation, and each day for the following eight days. The weights showed an increase
from day one to days eight, with the weight remaining above the baseline for all three
ferrets throughout the duration of the experiment. These data are displayed below in
Figure 3.5. When the weights were compared on a day to day basis, 83.33% of the total
recorded weights showed an increase from the previous day. The peak weight loss
occurred at day seven, with a single ferret exhibiting a weight change of -9.9 grams in 24
hours, but upon conclusion of this experiment, this particular ferret showed a final
percent gain of 14.77%, a gain of 133.40 grams. The final weight change from the
baseline for the three ferrets upon conclusion of the experiment were 14.77%, 17.19%,
and 14.57%. The ferrets were monitored daily over a nine-day period for temperature
changes as well. Animals in the B/Brisbane inoculation group exhibited changes in body
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temperature that ranged from 1.66 to -0.29 degrees Celsius from the initial temperature
taken on inoculation day, shown below in Figure 3.6. Of the 24 temperatures recorded
post-inoculation, 91.97% percent showed an increase in temperature from the initial
value observed on day 0. The elevations were first observed on day one post-inoculation
(day two indicated by Figure 3.6) and were maintained through day nine in all three
animals. The final temperatures taken on day nine for the three ferrets showed a positive
value in relation to the baseline.

Figure 3.5 (left): Percent of weight change in ferrets infected with B/Brisbane virus.
Figure 3.6 (right): Percent of temperature change in ferrets infected with B/Brisbane virus.

The nasal wash TCID50 values were compared for three ferrets over the course of
seven days, as shown below in Figure 3.7. On day one, the value showed an average of
103 TCID50/mL for the nasal wash virus titer. The average value then increased until day
three, to a value of 105 TCID50/mL. After day three, the value drastically decreased over
the course of two days until a combined average TCID50 value of 10.5 TCID50/mL was
obtained. The titer value remained at this value for the next three days indicating no
further viral activity in the nasal wash. These results indicated that the IBV was present in
the upper respiratory system until day five post-inoculation. These results resembled the
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results obtained from the Cal09 inoculum group, indicating similar upper respiratory
kinetics between the two influenza types. The kinetics between the two types of influenza
differed in viral infection time and length of infection. Influenza A appeared to peak in
the nasal wash 24 hours after inoculation, but the virus was no longer active in the upper
respiratory system at day four. Influenza B, B/Phuket, took three days to reach peak
upper respiratory infection, and lasted five days post-inoculation.

Figure 3.7: TCID50 values for ferrets UL-61, LL-62, and LR-62, over the course of seven days.

B/Phuket/3073/2013 (BYam)
B/Phuket/3073/2013 (BYam), was the second influenza B strain utilized for this
particular study. The B/Phuket virus in the Yamagata lineage, represent one of two
lineages of influenza virus (BYam and BVic) that have circulated in humans since the
mid-1980’s and were included in the 2014-15 seasonal influenza vaccination for the
Northern Hemisphere. Cal09 was used to verify the methods and applied as a control
group before proceeding with IBV infection. B/Brisbane was used to evaluate the kinetics
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of upper respiratory infection concerning IBV. Similar methods were used for the
evaluation of the kinetics of the B/Phuket virus, however a lung titer was included in this
experiment to observe viral infection of influenza B in the lower respiratory system. The
four ferrets were monitored for nine days, with weight, temperature, nasal wash titer, and
lung titer data recorded.
The weight of four ferrets was recorded for nine days post-inoculation. Like the
ferrets in the B/Brisbane inoculation group, the weights at day nine were measured as
above the baseline, as shown below in Figure 3.8. Similarly, a majority of the weights
remained above the baseline for the duration of the study, fluctuating during the nine day
experiment. The largest decline in weight could be seen on day two, with two ferrets
exhibiting an average 1.56% decline in body weight during the 24-hour period. The peak
weight change below the baseline exhibited a 1.35% decrease but increased to above the
baseline on the day following. Throughout the experiment, 93.75% of the 32 weights
recorded, remained at a positive value in relation to the baseline. When compared day to
day, 68.75% of the total weights recorded, exhibited an increase. These data indicate a
large fluctuation in weight throughout the experiment. Upon completion of the
experiment, the final percent weight change for the four ferrets were 6.09%, 8.37%,
6.01%, and 7.37%. Temperature was monitored and recorded for the B/Phuket inoculum
group for nine days, shown below in Figure 3.9. The temperature changes ranged from
1.06 to -0.45 degrees Celsius from the baseline. The increase in temperature can be seen
on the day following inoculation, similar to the B/Brisbane inoculum group. On day five,
two ferrets exhibited temperatures below the baseline. The temperatures recorded below
the baseline were a minor -1.29%, drastically increasing to at or above the baseline on
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day six. The temperatures then remained elevated after day six for the remainder of the
experiment. By day nine, all animals held temperatures above the initial baseline. Of the
32 temperatures recorded through the duration of this experiment, 87.5% exhibited a
positive value above the baseline.

Figure 3.8 (left): Percent of weight change in ferrets infected with B/Phuket.
Figure 3.9 (right): Percent of temperature change in ferrets infected with B/Phuket.

Two different B/Phuket inoculum groups were used to examine the kinetics of
influenza B. The ferrets 51-54 in the first group were used to collect data regarding
clinical symptoms and nasal wash infectivity. Ferrets 81-84 were used to collect data on
nasal wash and lung infection. The four ferrets in group one inoculated with B/Phuket
showed a low nasal wash TCID50 value on day one, an average of 101 TCID50/mL. The
data, shown below in Figure 3.10 shows a drastic increase until day two post-inoculation,
with a value of 104 TCID50/mL. These data are similar to what was seen in the
experiment with B/Brisbane infection. The nasal wash titers then decrease over the
course of four days to achieve a value equivalent to day one. The value remains at 101
TCID50/mL for four consecutive days. This indicates no further B/Phuket activity in the
upper respiratory system, similar to what B/Brisbane and Cal09 exhibited. The length of
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infection is similar to data observed in the B/Brisbane inoculum group, taking course
over six days post inoculation.

Figure 3.10: TCID50 values for ferrets UL-51, LL-52, UR-53, and LR-54, over the course of nine days.

To verify the data collected on B/Phuket, the nasal wash TCID50 values for ferrets
81-84, were analyzed and recorded in Figure 3.11 below. The day one data appeared to
be similar to the previous ferrets with a value of 101 TCID50/mL. The data then, similarly,
increased drastically after day one, except now over the course of two days, 1.25x105.
This indicated that the virus was able to replicate efficiently and to high titer values. The
data then decreased at about the same rate as it increased and a value of 7.5x104
TCID50/mL was observed on day four. This confirms the progression and kinetics of
B/Phuket in the upper respiratory system. To keep parameters similar to the experiment
concerning Cal09, lung samples were collected on day five, not allowing the virus to
reach inactivity in the nasal wash.

35

Figure 3.11: TCID50 values for ferrets UL-81, LL-82, UR-83, and LR-84, over the course of five days.

To evaluate the kinetics of an IBV in the lower respiratory system, lung titers
were sampled from the second B/Phuket inoculum group. Samples from the B/Phuket
group, ferrets 81-84, were harvested on day five post-inoculation. The samples were
homogenized, and the tissue homogenates were clarified by centrifugation and titrated in
48-well and 96-well tissue culture plates continag a monolayer of MDCK cells. The data
was obtained in the same way used for nasal wash samples. The data obtained, shown
below in Figure 3.7, show no presence of virus residing in the lungs at day five in the
experiment. When compared to Cal09, the lung data provides a difference between
influenza A and influenza B in the lower respiratory system.
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Figure 3.12: TCID50 value shows no virus detected in the lungs of ferrets 81-84.
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CHAPTER FOUR
Discussion and Conclusion

Viral Titers
In this study, the kinetics of influenza A and B were observed. The variables used
were able to characterize the ferret response and virus shedding and localization after
infection with influenza A and B. The influenza A virus used, Cal09, showed viral
localization in the upper respiratory tract during the beginning of infection. The viral titer
showed a high presence of virus in the nasal wash shortly after inoculation, with the
highest virus titer recorded on day one post-inoculation. The viral presence slowly started
to decrease over the course of infection, until little trace of virus was detected on day
four. Lung homogenates were collected after viral nasal wash activity was observed,
showing a positive viral titer for the lower respiratory system. The influenza B viruses,
B/Brisbane and B/Phuket, showed different viral shedding and localization. In the nasal
wash, the virus titer did not peak until days two or three post-inoculation. The viral titer
then decreased over the next few days, with the viral titers indicating viral activity until
days five to six. These results express the rate of viral infection in the upper respiratory
system, with influenza A infecting at an increased rate, and only lasting around four days.
Influenza B, however, took 24-48 hours to reach peak infection, and viral infection lasted
approximately five to six days. Viral infection was then noted in the lower respiratory
system, with influenza A showing infection in the lungs, and influenza B (B/Phuket)
showing no infection in the lungs. These data indicate that influenza A has an increased
viral infection and localization rate when compared to influenza B.
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Weight and Temperature
The weights observed during influenza A infection appear to corelate with the rate
of infection. On the first few days when maximum virus load was indicated, the weights
decreased drastically, When virus titers for the nasal wash started to drastically decrease
around days two and three, the weights began to increase to near the initial weight prior
to inoculation, but still showed an average percent weight change of -3.95%. The data
collected indicates that influenza A viral infection does affect weight, but not over a
substantial amount of time. In influenza B infection, the weights displayed different
characteristics, showing almost opposite results. The weights did not appear to correlate
with the degree of viral infection. Instead, increased weights were observed throughout
the nine days, regardless of the virus titer for the nasal wash. On day nine, ferrets
inoculated with B/Brisbane showed an average percent weight change of 15.51%, with
83.33% of the data showing an increase on a daily basis. This indicates a steady, almost
linear increase in weight throughout the duration of the experiment. In ferrets inoculated
with B/Phuket, the weights increased similarly. On day nine, the average percent weight
gain was 6.96%, with 68.75% of the data displaying an increase in weight on a daily
basis. When the influenza B infections are grouped together, it can be concluded that
weight gain is observed during influenza B infection.
Aside from different characteristics recognized for weight, temperature for
influenza A and B showed similar characteristics. On day one post-inoculation, half of
the ferrets infected with influenza A showed a drastic increase in temperature, while the
other half showed a decrease in temperature. Similar to this finding, the statistics were the
same when temperature was compared on a day to day basis. Throughout the study, 50%

39

of the data showed an increase in daily temperature while the other 50% showed a
decrease in daily temperature. Apart from these fluctuations in temperature observed
during the duration of this study, the temperatures on day four after influenza A infection
showed an average increase in percent temperature change of 1.81%. The temperature did
not show a correlation to viral infection on a day to day basis, but upon conclusion of
experimentation, an increased percent change in temperature of all four ferrets indicates a
relationship to influenza A infection. The temperature change in influenza B infection
was more prominent. In B/Brisbane infection, the temperature appeared increase almost
immediately after inoculation and remained elevated throughout the experiment. On day
nine, an average percent temperature change of 1.76% was noted. In B/Phuket infection,
temperature change was similar. The temperature appeared to increase immediately after
inoculation and remained elevated. On day nine, an average percent temperature change
of 2.03% was observed. In influenza B infection, it can be concluded that temperature
will increase during upper respiratory infection, and will remain elevated for days
following, regardless of detection of virus in the nasal wash. In influenza A infection, it
can be concluded that temperature may not indicate viral infection on a daily basis, but
over time a positive percent temperature change can be noticed.

Why Influenza B?
In a study conducted by Lakdawala et al. (2015), on the kinetics of H1N1 pdm
virus A/California/07/2009, the data published resemble the results and methods
presented in this study. In the study by Lakdawala, titers were collected and analyzed for
days one, three, and five in different parts of the respiratory tract. The Cal09 virus
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showed a positive mean virus titer in the soft palate, nasal wash, right mid lung, and the
left cranial lung. This indicated that the IAV was able to infect both the upper and lower
respiratory systems, similar to what was observed in the data concerning Cal09 presented
in this study. In a different study conducted by Moore et al. (2014), the inoculum volume
and its effect on clinical disease was evaluated using two strains of IAV. The effects of
IAV infection were analyzed using recorded data for weight change, temperature change,
nasal symptoms, and infection in the upper and lower respiratory system. The samples
quantified using TCID50 values displayed, over a course of six days post-inoculation, that
the weights of twelve ferrets appeared to decrease at a relatively steady rate (Moore et al.,
2014). This data presented by Moore confirms the results obtained in this study. In
Moore’s study, the temperature appeared to differ drastically from the baseline over the
course of six days post-inoculation, in most cases, remaining above the baseline over the
duration of data collection (Moore et al., 2014). The data presented in this current study,
resembles the data Moore published as well. The TCID50 values for this current study
read the highest in the nasal turbinates, but also showed a positive value in the combined
lung indicating infection in the upper and lower respiratory tract. The same ideas and
methods from Moore and Lakdawala were applied to this current study, however, for this
particular study, IBV infection was included. The studies from Lakdawala and Moore
provide a basis for the study of the kinetics concerning influenza A and lead to the study
of kinetics involving influenza B infection.
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Discussion
Influenza is a communicable disease that affects both the upper and lower
respiratory tract. There are four subtypes of influenza, some of these infecting humans
and others specific to different species (Center for Disease Control and Prevention,
2019). Influenza virus is transmissible through respiratory droplets expelled from the
mouth and respiratory system (Boktor, 2019). Influenza can be transmitted before the
carrier is symptomatic and until five to seven days post-infection (Center for Disease
Control and Prevention, 2018). It may take a few days to weeks for the carrier to fully
recover, but complications may arise during this recovery period. The complications that
may arise are usually inflammation of the upper respiratory tree and the trachea.
Respiratory complications arising due to influenza infection can develop in as little as 48
hours from the beginning of symptoms (Boktor, 2019). The virus replicates in the upper
and lower respiratory passages starting from the time of inoculation and peaking after 48
hours on average (Boktor, 2019). Research has suggested that influenza A and B are
different in terms of kinetics within the respiratory tract. This is what is evaluated
through this study. Influenza viruses replicate in the epithelial cell lining of the upper and
lower respiratory, and the pathology does not differ between natural or experimental
infection (Taubenberger, 2008). This allows for the methods used in this study. Many
studies have been conducted concerning the kinetics of influenza A. This study has
verified that influenza A, specifically strain Cal09, infects the upper respiratory system
and well as the lower. The study by Moore et al. (2014), concluded that within
experimental infection, influenza A was able to infect the nasal wash and two locations in
the lung. The researchers showed that the virus was able to infect a larger portion of the
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lung sections as the inoculum volume was increased (Moore et al., 2014). They were able
to conclude that the inflammatory response was most intense on day six following
inoculation. In this study, it was verified that influenza A infection in the nasal wash
peaks around 0-48 hours post infection. The titer value then showed a steady decrease as
the host cleared the virus from the upper respiratory tract. Upon completion of nasal wash
collection, the ferrets were euthanized, and the lungs were sampled. The titer verified that
there was influenza A virus present in the lungs at this time, with little to no virus present
in the nasal wash.
Similar procedures were used for the evaluation of influenza B. Less information
is known about the kinetics of influenza B, making it hard to fully determine if IBV
infects the lower respiratory system. The first virus used, B/Brisbane, confirmed infection
of the upper respiratory system. However, unlike influenza A, the virus titer showed a
peak concentration on day three, 72 hours after inoculation. The titer value then
drastically decreased until little to no virus was present. Another virus, B/Phuket, was
used to study infection of the lower respiratory system. B/Phuket showed nasal wash
virus titers similar to Cal09 and B/Brisbane. The virus titer showed the highest on day
two, but still remained quite high on day three. The titer for B/Phuket then dropped to a
value indicating no viral activity around day six. Regardless of the small inconsistencies,
in all three strains of influenza, the virus titer peaked around 48 hours post infection, and
was no longer active in the upper respiratory tract around day five. The lung titer was
then analyzed to determine the presence of B/Phuket in the lower respiratory system.
There was no presence of virus in any of the four ferrets inoculated with B/Phuket. The
information presented in this report confirms the kinetics of influenza A and B in the
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upper respiratory system and also confirms that although influenza A infects the lower
respiratory system, influenza B (B/Phuket) does not. B/Brisbane was not included in lung
sampling, therefore, further research would need to be conducted to confirm the lung
infectivity of this type of influenza B virus.
Conclusion
In this study, the kinetics of influenza A was verified and determined to infect
both the upper and lower respiratory systems. The experiments evaluating influenza B
were able to verify that the IBV infects the upper respiratory system, but no sign of lower
respiratory infection was found in this study. Currently, little is known about the viral
kinetics of influenza A and B during infection within an individual. World-wide
influenza outbreaks can be very costly in terms of human life, infecting nearly 20-50
million people in the United States alone and causing an estimated 30-40,000 deaths per
year. Influenza viruses have an extremely high mutation rate, providing a large hurdle for
effective vaccinations. This constant change creates an unquestionable need for intensive
basic and clinical influenza research. The goal is to recognize and anticipate how the
viruses are evolving. This includes the kinetics and the replication of the virus. This
thorough understanding is the first step toward creating accurate and useful antiviral
therapies for influenza. As seen in the world today with COVID-19, not understanding
the kinetics and infectivity of a virus can be particularly damaging to the population and
economy. Influenza has been around for hundreds of years, allowing adequate time for
extensive research. Research such as this is needed to keep up with the quickly evolving
influenza in order to create a healthier society and economy.
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